


# Buy on dips in equities

## Prepare for market volatility

Author: Sagar Khandelwal, Strategist, UBS Switzerland AG

- Why? (1) Fed interest rate cuts in non-recession periods have historically been favorable for equities. (2) We believe exposure to artificial intelligence will prove key to long-term portfolio growth. (3) Phasing-in strategies can help investors manage near-term volatility while capturing longer-term gains.
- Why now? (1) We expect the S&P 500 to rise to 6,600 by year-end and to 6,800 by June 2026. (2) Moderate investor positioning and robust realized earnings growth suggest to us that markets are not in a bubble. (3) US technology, health care, utilities, and financials; select Asian markets; and quality and thematic opportunities in Europe all offer attractive growth prospects, in our view.



We think that investors underallocated to stocks should consider phasing strategies and/or prepare to add exposure on potential market dips.

We believe the equity bull market remains intact and expect an economic soft landing, solid corporate earnings, and lower interest rates to support markets over the next 12 months. We see opportunities across regions:

#### US: Technology, health care, utilities, and financials

In the US, we expect the strongest performance to come from the technology, health care, utilities, and financial sectors:

Technology: In the short term, we believe that investors need to be mindful of the risk of a period of "capex indigestion," as incremental revenue growth continues to lag incremental capex growth at big tech companies. However, over the medium and longer term, exposure to Al will prove essential to long-term portfolio growth, in our view. Underlying consumer and business use of Al is already outpacing expectations, and Al solution providers are making good progress converting usage into revenue. We believe that the scope to monetize will expand further, and we remain confident that technology companies will ultimately earn an attractive return on the investments they are currently making.

Health care: The pharmaceutical industry faces significant uncertainty not only from tariffs but also from Trump's push for Most Favored Nation (MFN) drug pricing, although much of the potential negative consequences of these two policy risks is already priced in. Resolution of these two policy overhangs should materially improve sentiment and provide a meaningful valuation lift. We continue to rate the US health care sector as Attractive. Promising new therapies in large, untapped markets—such as obesity and Alzheimer's —should help offset patent expirations.

*Utilities:* The sector's defensive characteristics should offer ballast in a portfolio if economic growth slows further. In addition, roughly 20-25% of the sector has material exposure to Al power demand.

Financials: Easing regulation, early signs of a pick-up in capital market activity, and improving net interest margins should support a recovery. Ongoing growth in payments, driven by digital adoption and robust transaction volumes, adds further momentum. We believe these positive trends, alongside solid fundamentals, position the sector well for the months ahead.

This report has been prepared by UBS Switzerland AG. **Please see important disclaimers and disclosures at the end of the document.** 

#### Asia: Singapore, India, and China's tech sector

Singapore: Singapore stands out as a relative "safe haven," backed by its strong currency, high dividend yields, and local equity market reforms. Easing trade tensions also bode well for its trade-reliant economy. For global investors, the market offers high dividend yields and currency diversification benefits.

India: We continue to believe the current elevated US tariffs on India are unlikely to be permanent in nature, and there is scope for India to offer concessions. While the Indian equity market could remain volatile in the near term, its relatively closed economy and its lower dependence on exports will likely help blunt the economic impact. We believe Indian equities will be driven by double-digit earnings growth over the next two years, and we expect private consumption and government spending to continue to support the economy.

China tech: We continue to favor China's tech sector, which is supported by new advancements, growing Al adoption, bottom-up fundamental improvements, and domestic policy support. The sector's valuations are still reasonable, earnings growth is expected to be strong (~20% for 2025E), and currency appreciation could provide a further lift. We prefer leading names in online gaming, cloud services, and online travel agencies.

#### Europe: Quality, industrials, and thematic plays

Six ways to invest in Europe: The increasing hope of a ceasefire and peace between Russia and Ukraine could lead to improving consumer, business, and market sentiment across Europe, as well as some benefits through lower energy prices and a focus on rebuilding Ukraine. A potential easing of Russian sanctions could add additional upside to equity markets. There are still many unknowns, however, and we recommend our "Six ways to invest in Europe" theme, which selectively includes some of the beneficiaries of a potential truce. Other key trends in the region include market volatility, policy shifts in Germany, and increased defense and cybersecurity spending.

Swiss high-quality dividends and income strategies: We think Swiss dividend-paying equities are attractive, as the average dividend yield, at around 3%, is higher than that of Swiss franc bond yields. With robust balance sheets and profitability, we think this suggests that market-wide distributions are sustainable.

European quality: We rate European quality stocks as Attractive, as we see an appealing entry point. These companies' strong profitability, resilient earnings, and solid balance sheets make them well suited to a late-cycle, volatile environment. Historically, quality stocks have outperformed during periods of slow growth and uncertainty, and much of the direct tariff risk now appears priced in. We see a compelling risk-reward for broad-based exposure.

European industrials: We hold a positive outlook on European industrials given the long-term structural growth and near-term catalysts. The sector trades at a forward P/E discount to US industrials, offers structural growth exposure to our Power and resources theme, and would benefit from reshoring manufacturing and materially higher European defense equipment spending. In addition, the sector should benefit from a pick-up in global manufacturing activity, supported by an end of destocking in China—an important end-market for several large European industrials.

#### **Brazil: Still constructive**

Brazil is a relatively closed economy, with exports to the US representing less than 2% of GDP. The direct impact on economic activity and corporate earnings from tariffs will likely be contained, and Brazilian stocks should continue to be supported by a weaker US dollar, ongoing interest in geographic diversification by global investors, improving corporate returns on equity, and the prospect of central bank rate cuts.

### **Appendix**

#### **Risk information**

UBS Chief Investment Office's ("CIO") investment views are prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS"), part of UBS Group AG ("UBS Group"). UBS Group includes former Credit Suisse AG, its subsidiaries, branches and affiliates. Additional disclaimer relevant to Credit Suisse Wealth Management follows at the end of this section.

The investment views have been prepared in accordance with legal requirements designed to promote the **independence** of investment research.

#### **Generic investment research – Risk information:**

This publication is **for your information only** and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein does not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific recipient. It is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and market prices indicated are current as of the date of this report, and are subject to change without notice. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria. UBS may utilize artificial intelligence tools ("Al Tools") in the preparation of this document. Notwithstanding any such use of Al Tools, this document has undergone human review.

In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information.

Different areas, groups, and personnel within UBS Group may produce and distribute separate research products **independently of each other**. For example, research publications from **CIO** are produced by UBS Global Wealth Management. **UBS Global Research** is produced by UBS Investment Bank. **Research methodologies and rating systems of each separate research organization may differ**, for example, in terms of investment recommendations, investment horizon, model assumptions, and valuation methods. As a consequence, except for certain economic forecasts (for which UBS CIO and UBS Global Research may collaborate), investment recommendations, ratings, price targets, and valuations provided by each of the separate research organizations may be different, or inconsistent. You should refer to each relevant research product for the details as to their methodologies and rating system. Not all clients may have access to all products from every organization. Each research product is subject to the policies and procedures of the organization that produces it. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking, sales and trading or principal trading revenues, however, compensation may relate to the revenues of UBS Group as a whole, of which investment banking, sales and trading and principal trading are a part.

Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in

general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein. This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. For information on the ways in which CIO manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit <a href="https://www.ubs.com/research-methodology">www.ubs.com/research-methodology</a>. Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor.

**Important Information About Sustainable Investing Strategies**: Sustainable investing strategies aim to consider and incorporate environmental, social and governance (ESG) factors into investment process and portfolio construction. Strategies across geographies approach ESG analysis and incorporate the findings in a variety of ways. Incorporating ESG factors or Sustainable Investing considerations may inhibit UBS's ability to participate in or to advise on certain investment opportunities that otherwise would be consistent with the Client's investment objectives. The returns on a portfolio incorporating ESG factors or Sustainable Investing considerations may be lower or higher than portfolios where ESG factors, exclusions, or other sustainability issues are not considered by UBS, and the investment opportunities available to such portfolios may differ.

**External Asset Managers / External Financial Consultants:** In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

**USA:** Distributed to US persons only by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS SuMi TRUST Wealth Management Co., Ltd., UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. **UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.** 

For country information, please visit <u>ubs.com/cio-country-disclaimer-gr</u> or ask your client advisor for the full disclaimer.

#### Additional Disclaimer relevant to Credit Suisse Wealth Management

You receive this document in your capacity as a client of Credit Suisse Wealth Management. Your personal data will be processed in accordance with the Credit Suisse privacy statement accessible at your domicile through the official Credit Suisse website. In order to provide you with marketing materials concerning our products and services, UBS Group AG and its subsidiaries may process your basic personal data (i.e. contact details such as name, e-mail address) until you notify us that you no longer wish to receive them. You can optout from receiving these materials at any time by informing your Relationship Manager.

Except as otherwise specified herein and/or depending on the local Credit Suisse entity from which you are receiving this report, this report is distributed by UBS Switzerland AG, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA).

Version A/2025. CIO82652744

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.